

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross® has confirmed that the shortage for Taro-Calcipotriol/Betamethasone 50 mcg/g 0.5 mg/g Gel (DIN 02525178) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 26, 2024**. The following grouping was removed from the Critical Supply Product List **August 27, 2024**.

CALCIPOTRIOL MONOHYDRATE / BETAMETHASONE DIPROPIONATE

50 MCG / G / 0.5 MG / G TOPICAL GEL

00002525178	TARO-CALCIPOTRIOL / BETAMETHASONE	TAR	\$ 1.3142
00002319012	DOVOBET	LEO	\$ 1.6539

Alberta Blue Cross has confirmed that the shortage for Caspofungin 70 mg/vial Injection (DIN 02460955) manufactured by Juno Pharmaceuticals Corp. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 27, 2024**. The following grouping was removed from the Critical Supply Product List **August 28, 2024**.

CASPOFUNGIN

70 MG / VIAL INJECTION

00002460955	CASPOFUNGIN	JUN	\$ 188.7000
00002244266	CANCIDAS	MFC	\$ 222.0000

Alberta Blue Cross has confirmed that the shortage for Pinaverium 100 mg Tablet (DIN 02469685) manufactured by AA Pharma Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 27, 2024**. The following grouping was removed from the Critical Supply Product List **August 28, 2024**.

PINAVERIUM BROMIDE

100 MG TABLET

00002469685	PINAVERIUM	AAP	\$ 0.5346
00002230684	DICETEL	BGP	\$ 0.7215

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Teva-Buprenorphine/Naloxone 2 mg/0.5 mg Sublingual Tablet (DIN 02453908) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 27, 2024**. The following grouping was removed from the Critical Supply Product List **August 28, 2024**.

BUPRENORPHINE HCL / NALOXONE HYDROCHLORIDE DIHYDRATE

2 MG / 0.5 MG SUBLINGUAL TABLET

00002424851	PMS-BUPRENORPHINE / NALOXONE	PMS	\$ 1.3350
00002453908	TEVA-BUPRENORPHINE / NALOXONE	TEV	\$ 1.3350
00002295695	SUBOXONE	IUK	\$ 2.7261

Alberta Blue Cross has confirmed that the shortage for Dextroamphetamine 5 mg Tablet (DIN 02443236) manufactured by AA Pharma Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 3, 2024**. The following grouping was removed from the Critical Supply Product List **September 3, 2024**.

DEXTROAMPHETAMINE SULFATE

5 MG TABLET

00002443236	DEXTROAMPHETAMINE	AAP	\$ 0.5081
00001924516	DEXEDRINE	PAL	\$ 0.7012

Alberta Blue Cross has confirmed that the shortage for Octreotide 20 mg/vial Injection (DIN 02503778) manufactured by Teva Canada Limited has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 7, 2024**. The following grouping was removed from the Critical Supply Product List **September 5, 2024**.

OCTREOTIDE ACETATE

20 MG / VIAL INJECTION

00002503778	OCTREOTIDE	TEV	\$ 1,279.9350
00002239324	SANDOSTATIN LAR	NOV	\$ 1,699.8900

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

